Best Practice & Research Clinical Haematology

Papers
(The TQCC of Best Practice & Research Clinical Haematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Contemporary and future strategies in polycythemia vera55
The role of randomized controlled trials, registries, observational databases in evaluating new interventions24
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation22
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes21
Endpoint selection and evaluation in hematology studies18
Coagulopathy in COVID-19 and anticoagulation clinical trials18
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)17
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL17
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances14
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program14
Advances in CAR design13
The presentation of results from studies in clinical haematology13
Editorial Board13
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults13
Take a spin: Apheresis in the care of adult leukaemia patients13
Creating a GMP cell processing program: A focus on quality and regulation12
Vaccine-induced immune thrombotic thrombocytopenia12
Blood coagulation and cancer genes11
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma11
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms10
Targeted cellular therapy for treatment of relapsed or refractory leukemia10
Accelerated and blast phase myeloproliferative neoplasms10
Principles of cost-effectiveness studies and their use in haematology9
Cancer associated thrombosis in pediatric patients9
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”9
Dysregulation of Protein S in COVID-199
What should be done and what should be avoided when comparing two treatments?9
The international cooperative Gaucher group (ICCG) Gaucher registry9
Editorial Board8
Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma8
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?7
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma7
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration7
Clinical experience of CAR T cells for multiple myeloma7
Addressing symptom burden in myeloproliferative neoplasms7
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders7
The role of registries in hematological disorders7
Handling missing covariate data in clinical studies in haematology6
Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation6
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies6
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment6
Thrombosis and bleeding in hematological malignancy6
Anti-GM-CSF autoantibodies in myeloid leukemias6
How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?6
CAR assembly line: Taking CAR T-cell manufacturing to the next level5
Cytokines in hematopoietic cell transplantation and related cellular therapies5
Recent progress in acute leukemia and myelodysplasia5
Advances in polycythemia vera and lessons for acute leukemia5
Challenges in anticoagulation for patients with brain tumors5
What is the role of the bone marrow microenvironment in AML?5
A reflection on Arnold Caplan, the father of MSC5
Editorial Board / Aims & Scope5
Preface5
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia5
0.10219097137451